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ABSTRACT
Star–PAP is a non-canonical, nuclear poly(A) poly-
merase (PAP) that is regulated by the lipid signaling
molecule phosphatidylinositol 4,5 bisphosphate
(PI4,5P2), and is required for the expression of a
select set of mRNAs. It was previously reported
that a PI4,5P2 sensitive CKI isoform, CKIa associ-
ates with and phosphorylates Star–PAP in its cata-
lytic domain. Here, we show that the oxidative
stress-induced by tBHQ treatment stimulates the
CKI mediated phosphorylation of Star–PAP, which
is critical for both its polyadenylation activity and
stimulation by PI4,5P2. CKI activity was required
for the expression and efficient 30-end processing
of its target mRNAs in vivo as well as the
polyadenylation activity of Star–PAP in vitro.
Specific CKI activity inhibitors (IC261 and CKI7)
block in vivo Star–PAP activity, but the knockdown
of CKIa did not equivalently inhibit the expression of
Star–PAP targets. We show that in addition to CKIa,
Star–PAP associates with another CKI isoform, CKIe
in the Star–PAP complex that phosphorylates Star–
PAP and complements the loss of CKIa. Knockdown
of both CKI isoforms (a and e) resulted in the loss of
expression and the 30-end processing of Star–PAP
targets similar to the CKI activity inhibitors. Our
results demonstrate that CKI isoforms a and e
modulate Star–PAP activity and regulates Star–PAP
target messages.
INTRODUCTION
In eukaryotes, the generation of messenger RNA (mRNA)
is a highly orchestrated process comprised of a number of
events, including transcription, splicing, capping and
30-end processing followed by export to the cytoplasm
for translation (1–4). The 30-end processing of mRNA pre-
cursors (pre-mRNA) is an essential step in eukaryotic gene
expression which involves two tightly coupled processes—
endonucleolytic cleavage followed by the subsequent
addition of a poly(A) tail (200–300 adenosine nucleotides)
to the cleaved RNA (5–11). The polyadenylation of
mRNAs is required for their export, stability, and efﬁcient
translation (5,10,12).
Polyadenylation of pre-mRNA is carried out by a class
of enzymes called poly(A) polymerases (PAPs), which add
a poly(A) tail to the 30-end of cleaved RNA (13,14). PAPs
function as a part of 30-end processing complex (5,10)
comprising of cleavage and polyadenylation speciﬁcity
factors (CPSF-160, -100, -73 and -30 subunits) (15),
cleavage stimulatory factors (CstF-77, -64 and -50
subunits) (16), cleavage factors I and II (CF I and
CF II) (17,18), the scaffolding protein symplekin (19,20)
and poly(A) binding protein (PABP) (21). There are
multiple genes encoding PAPs in mammalian cells,
including Trf4, GLD2 and PAPa, which are involved in
degradation, mRNA stability, and the polyadenylation of
newly transcribed mRNAs respectively (10,22,23).
Star–PAP is a newly identiﬁed, nuclear PAP that is
regulated by the lipid messenger phosphatidylinositol-4,
5-bisphosphate (PI4,5P2). Star–PAP is required for the
expression of select target messages, including heme
oxygenase 1 (HO-1) (24). Star–PAP couples to the tran-
scriptional machinery to polyadenylate messages. Like
PAPa, Star–PAP has a PAP domain and an RNA recog-
nition motif; but the PAP domain of Star–PAP is split by
a proline-rich region. Additionally, Star–PAP contains a
zinc ﬁnger motif at the N-terminus (24). Star–PAP binds
its target pre-mRNA that requires both ZF and RRM
domains, recruits CPSF subunits to the poly(A) site and
assembles into a distinct 30-end processing complex (25).
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proteins, such as phosphatidylinositol-4-phosphate
5-kinase I alpha (PIPKIa) and the PI4,5P2-senstive
protein kinase casein kinase Ia (CKIa) both of which
are also required for the expression of some of its target
mRNAs (24,26).
CKIa is a PI4,5P2-sensitive protein kinase, a member of
the CKI family of Serine/Threonine (S/T) speciﬁc protein
kinases (27–29). CKIs are ubiquitous monomeric protein
kinases in the size range from 35 to 55KDa present in the
membrane, nucleus, cytoplasm, cytoskeleton and spindles
of mammalian cells (30,31). CKI phosphorylates a large
number of proteins and its substrate selection in vivo is
regulated by subcellular localization and/or docking sites
on the speciﬁc substrate (27,28). CKI activity is regulated
through a distinct recognition motif (S/T)(P)XX(S/T),
where (S/T)(P) represents a phosphoserine or
phosphothreonine residue, and the underlined S/T repre-
sents the CKI target site. This indicates that modiﬁcation
of serine or threonine residues by CKI requires the
preceding phosphorylation of amino acid residues
N-terminal of the target sequence (32–34). CKI also phos-
phorylates a related unprimed site, which optimally
contains a cluster of acidic amino acids N-terminal to
the target S/T, including an acidic residue at N   3 and
a hydrophobic region C-terminal to the target S/T
(35–38). However, for several important CKI targets
such as NF-AT4 and beta-catenin, CKI does not require
N   3 priming, but instead phosphorylates the ﬁrst serine
in the non-canonical sequence S-L-S, which is followed by
a cluster of acidic residues, albeit less efﬁciently than the
optimal sites (39–41). In addition, a CKI docking
sequence (SDASSCE) has also been deﬁned on the tran-
scription factor NF-AT4 (A-2 domain), which is required
for its phosphorylation (41,42).
There are at least four splice variants of CKIa (CK1a,
CK1aS, CK1aL and CK1aLS), characterized by the
presence or absence of two additional coding sequences
(L or S insertions) in the catalytic domain and/or in the
regulatory domain (43–47). Exon ‘L’ encodes a 28-amino
acid stretch that is inserted after lysine 152, in the center of
the catalytic domain. The ‘S’ insert encodes 12 amino acid
residues and is located close to the carboxyl terminus of
the protein. The various splice isoforms of CKIa differ in
their substrate preference, kinase activity, biochemical
properties, subcellular localization and biological func-
tions in the cell (28,43,44,46,47). CKIa has been
reported to associate with cytosolic vesicular structures,
including small synaptic vesicles, the centrosome during
interphase, and with the mitotic spindle during mitosis
(30,48). In addition, CKIa localizes in the nucleus to
nuclear speckles (26,49) which harbor various proteins
required for RNA processing and transcription (50).
Inhibitors of CKI activity, such as IC261 and CKI7,
inhibit CKIa and other isoforms of CKI, including
CKId and CKIe (51). While CKI7 equally inhibits all
isoforms of CKI, IC261 has higher preference to inhibit
CKId and CKIe than CKIa (52–54). These CKI isoforms
have been implicated in circadian rhythm, DNA damage
and various other physiological functions in the cell
(51,55–57).
Previously, we have reported that Star–PAP associates
with multiple kinases, including CKIa (24,26). Here, we
show that tBHQ treatment stimulates CKI-mediated
phosphorylation of Star–PAP, and that, in addition to
CKIa, Star–PAP associates with another CKI isoform,
CKIe in the complex, which can complement for the loss
of CKIa in regulating Star–PAP activity. We demonstrate
that CKI activity is necessary for in vitro Star–PAP
polyadenylation activity and the 30-end processing of its
target messages in vivo. Our data indicate that the kinase
activities of both the isoforms of CKI—a and e modulate
Star–PAP polyadenylation activity and target mRNAs.
MATERIALS AND METHODS
Cell culture, transfections and cell stimulation
HEK-293 and HeLa cells were obtained from ATCC and
maintained in DMEM with 10% FBS at 37 Ci n5 %C O 2.
HeLa cells were transfected using Oligofectamine for
siRNA knockdown (Invitrogen). In HEK-293 cells, trans-
fections were accomplished by the calcium phosphate
method with 5–10mg of plasmid DNA. The knockdown
of CKIa or Star–PAP was carried out as described previ-
ously (24,26). To induce a transcriptional antioxidant
response, cells were treated for 4h with 100mM tert-
butylhydroquinone (tBHQ) in DMSO. Control cells
were treated with solvent control DMSO to a ﬁnal con-
centration of 0.1%. The CKI activity inhibitors CKI7 (53)
and IC261 (54) were dissolved in DMSO and used at a
ﬁnal concentration as indicated.
Expression and afﬁnity puriﬁcation of Star–PAP
Afﬁnity puriﬁed human Flag–Star–PAP was obtained
from HEK-293 cells with stably expressed Flag–Star–
PAP as described previously (24). For antioxidant
response, cells were treated with 100mM tBHQ in
DMSO for 4h and DMSO for the control cells.
Protein kinase assays
Protein kinase assays were performed in a 20-ml reaction
volume with 1  kinase buffer (25mM Tris–HCl, pH 7.5;
5mM b-glycerol phosphate; 10mM MgCl2; 0.1mM
sodium vanadate and 0.5mM DTT) as described previ-
ously (26). The reaction was initiated by adding 10mCi
of g
32P-ATP. For the inhibition studies, all reaction com-
ponents except ATP were incubated with the inhibitors for
45min on ice prior to starting the kinase assay. CKI7 or
IC261 were resuspended in DMSO and used at a ﬁnal
concentration of 5–100mM as indicated. Synthetic
PI4,5P2 was resuspended in 20mM Tris–HCl, subjected
to bath sonication to form micelle, and used at a concen-
tration of 25–100mM as indicated.
Immunoprecipitation and immunoblot analysis
Total cell lysates were prepared in buffer A [50mM Tris
(pH 7.4), 100mM KCl, 5mM EDTA, 5% NP-40, 5mM
NaF, 100mg/ml RNase A, 1mM NaVO4,5 0 m M
b-glycerol phosphate, and protease inhibitors] and gently
sonicated. Rabbit polyclonal anti-Star–PAP and
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(Upstate Biotechnology); rabbit polyclonal anti-actin
(Bethyl Laboratories); rabbit polyclonal anti-RNA poly-
merase II (N-20); rabbit polyclonal anti-CPSF-73 (Bethyl
Laboratories); mouse monoclonal anti-Flag M5 (Sigma);
rabbit polyclonal anti-CKIa (30); rabbit polyclonal
anti-CKIe (Bethyl Laboratories); mouse monoclonal
anti-CKId (Abcam); and rabbit polyclonal anti-CKII
(Bethyl Laboratories) were used for western blot and
RIP analysis. Antibodies were used between 1:1000–
1:2000 dilutions for immunoblot experiments.
30-RACE assay
Total RNA was extracted as described previously (24) and
30-RACE was carried out as described previously (25). The
cDNAs for the 30-RACE assays were synthesized using the
Smart RACE Kit (Clontech) according to manufacturer’s
instructions with 1mg of total RNA isolated from
HEK-293 cells. The gene speciﬁc forward primers for
HO-1 or GAPDH are 50-GACCTGCCCAGCTCTGGC
GAG-30 and 50-GTATGACAACGAATTTGGCTACAG
CAAC-30. The RACE products were conﬁrmed by
sequencing.
Quantitative real-time PCR (RT–qPCR)
Total RNA was extracted and reverse transcribed as
described previously (24). Target mRNA was quantiﬁed
with the MyiQ single-color real-time PCR detection
system and iQ SYBR Green Supermix (Bio-Rad).
Single-product ampliﬁcation was conﬁrmed by
melting-curve analysis, and primer efﬁciency was near
100% in all experiments. Quantiﬁcation is expressed in
arbitrary units, and target mRNA abundance was
normalized to the expression of GAPDH with the Pfafﬂ
method. All real-time RT–qPCR results were representa-
tive of at least three independent experiments. Primers
used for the PCR were CCACCAAGTTCAAGCAGC
TCTA (forward) and GCTCCTGCAACTCCTCAA
AGAG (reverse) for HO-1; GAAGGTCGGAGTC AAC
GGATTT (forward) and GAATTTGCCATGGGTGGA
AT (reverse) for GAPDH; AAGTT CTTGAAACTCTG
CAAGAGAAGG (forward) and (GCCTCAACTGTATT
GAACTCGGAC) for GCLC respectively.
RNA immunoprecipitation
RNA immunoprecipitation (RIP) experiments were per-
formed as described previously (25). The primers speciﬁc
to HO-1 used to study the association of CKIa and CKIe
were 50-TTCTGTTGTTTTTATAGCAG-30 as forward
and 50-TCAAACAGACCAGCTCCTG-30 as reverse.
In vitro polyadenylation assay
In vitro polyadenylation assay with Star–PAP puriﬁed
from the HEK-293 cells were performed using the
45-mer RNA oligonucleotide (UAGGGA)5A15 as an
RNA substrate as described previously (24). For inhib-
ition studies, the Star–PAP complex was isolated after
the treatment of the cells with CKI inhibitors for 3h.
For the polyadenylation assay with phosphatase
treatment, the samples were incubated with lamda phos-
phatase in RT for 30min before the initiation of the
polyadenylation reaction. Control samples were equally
incubated but without phosphatase.
RESULTS
The oxidative stress agonist tBHQ stimulates Star–PAP
phosphorylation
Previously, it had been shown that the Flag–Star–PAP
complex puriﬁed from cells retained associated kinase
activity toward Star–PAP and the generic protein kinase
substrates casein and myelin basic protein (MBP) (26).
One of the associated kinases that phosphorylated Star–
PAP was identiﬁed as the PI4,5P2-sensitive isoform of
CKI, CKIa (26), but it was not clear how these kinases
integrate into signaling pathways that regulate Star–PAP.
Since Star–PAP puriﬁed from cells treated with the oxida-
tive stress agonist, tert-Butylhydroquinone (tBHQ)
stimulated its polyadenylation activity (24), the effect of
tBHQ treatment on the phosphorylation of Star–PAP was
investigated. To assess kinase activity associated with the
Star–PAP complex, the Flag–Star–PAP complex was
isolated from HEK-293 cells stably expressing Flag–
Star–PAP after treatment with tBHQ or the DMSO
solvent control. The puriﬁed Star–PAP complex was
then subjected to an in vitro kinase assay using puriﬁed
Star–PAP and added casein or MBP as substrates.
Treatment of the cell with tBHQ stimulated a dramatic
increase in the phosphorylation of Star–PAP and exogen-
ous casein or MBP by the kinase activity associated with
the cell puriﬁed Star–PAP complex (Figure 1A). The phos-
phorylation of Star–PAP increased  10-fold, whereas
casein and MBP increased 3–6-fold upon tBHQ stimula-
tion compared to the untreated samples (Figure 1A and
B). Since the previously reported Star–PAP associated
kinase, CKIa is a PI4,5P2 sensitive kinase (29), we
analyzed the kinase assay in the presence of increasing
concentration of PI4,5P2 (Figure 1C). As previously
observed, the addition of PI4,5P2 to the kinase assay
with Star–PAP puriﬁed from the unstimulated cells in-
hibited the phosphorylation of Star–PAP. Signiﬁcant in-
hibition of phosphorylation was observed at 25–50mMo f
PI4,5P2 and a complete inhibition was obtained at 100mM
of PI4,5P2 (Figure 1C and Supplementary Figure S1A).
The stimulated phosphorylation of Star–PAP after the
pre-treatment of the cell with tBHQ was equally inhibited
by PI4,5P2. The signiﬁcant inhibition of kinase activity
required  50mM of PI4,5P2 with a complete inhibition
obtainable at  100mM (Figure 1C and Supplementary
Figure S1A).
To conﬁrm the role of CKI (or CKIa) in tBHQ-induced
Star–PAP phosphorylation, in vitro kinase assays were
carried out using the Star–PAP complex in the presence
or absence of the CKI activity inhibitors CKI7 and IC261.
Phosphorylation of Star–PAP was inhibited by 100mMo f
either CKI7 or IC261, equally in the presence or absence
of tBHQ treatment (Figure 1D). At higher concentration,
the CKI inhibitors CKI7 and IC261 have been reported to
inhibit other kinases (53,54,58). To conﬁrm that the
Nucleic Acids Research, 2011,Vol.39, No. 18 7963inhibition of Star–PAP phosphorylation by CKI7 and
IC261 was speciﬁc, in vitro kinase assays were further
carried out with low concentrations (5–15mM) of CKI7
and IC261. We consistently observed inhibition of Star–
PAP phosphorylation equally at 10 or 15mM of CKI7 or
IC261 in presence or absence of tBHQ treatment
(Supplementary Figure S2A and B). At a concentration
 5mM of the inhibitors, there was only partial inhibition
of Star–PAP phosphorylation (Supplementary Figure S2A
and B). However, the association of CKIa with Star–PAP
was not enhanced upon tBHQ treatment (Supplementary
Figure S1B), suggesting an increase in the kinase speciﬁc
activity or association of another kinase. Taken together,
these data indicate that the phosphorylation of Star–PAP
mediated by CKI activity is stimulated by tBHQ treatment
of the cell.
Phosphorylation of Star–PAP is critical for its
polyadenylation activity
Previously, we reported that tBHQ treatment stimulated
Star–PAP polyadenylation activity, and here we showed
that tBHQ-induced CKI-mediated Star–PAP phosphoryl-
ation. Therefore, phosphorylation may play an important
role in the regulation of Star–PAP activity. To test this,
the Flag–Star–PAP complex was puriﬁed from the
HEK-293 cells stably expressing Flag–Star–PAP after
tBHQ treatment or solvent DMSO (Figure 2A). The
puriﬁed Star–PAP complex was then treated with
-phosphatase for 30min at RT and then assayed for its
polyadenylation activity using an A15 RNA substrate by
an in vitro polyadenylation assay (24) in the presence or
absence of PI4,5P2. Treatment with tBHQ resulted in a
dramatic stimulation of the Star–PAP polyadenylation
activity upon PI4,5P2 addition when compared to untreat-
ed cells (Figure 2B, lane 4), which is consistent with the
previous ﬁnding that tBHQ priming is required for the
stimulation of Star–PAP polyadenylation activity by
PI4,5P2. When phosphatase treated, the puriﬁed Star–
PAP complex showed minimal activity regardless of
PI4,5P2 addition or tBHQ treatment (Figure 2B, lanes
5–8). There was a  6-fold reduction in the Star–PAP
polyadenylation activity after phosphatase treatment in
presence of PI4,5P2 from tBHQ unprimed and  20-fold
reduction from the tBHQ primed samples compared to
that of untreated Star–PAP (Figure 2C). Western blot
analysis showed equal amounts of Star–PAP in each
reaction lane (Figure 2C). The loss of Star–PAP activity
after phosphatase treatment indicates that phosphoryl-
ation is critical for both Star–PAP polyadenylation
activity and PI4,5P2 stimulation.
CKI activity mediated phosphorylation of Star–PAP
modulates Star–PAP polyadenylation activity in vitro
Star–PAP phosphorylation is inhibited by CKI inhibitors
in vitro. The expression of Star–PAP target mRNAs, such
as HO-1 was also blocked after the cells were treated with
CKI inhibitors (26). To determine if CKI (or CKIa) is the
critical kinase regulating Star–PAP activity, the Flag–
Star–PAP complex was puriﬁed from the HEK-293 cells
stably expressing Flag–Star–PAP following the
Figure 1. CKI-mediated Star–PAP phosphorylation is induced by tBHQ. (A) In vitro kinase assay of the Flag–Star–PAP complex puriﬁed from
HEK-293 cells stably expressing Flag–Star–PAP after treatment with tBHQ (100mM for 4h) or the solvent control, DMSO using Star–PAP, Casein
and Myelin basic protein (MBP) as substrates. The
32P incorporated and the total protein (coomasie-stained) are indicated. (B) Quantiﬁcation of the
kinase activity toward Star–PAP, Casein and MBP from the autoradiogram in A. The intensity in arbitrary unit is expressed relative to the tBHQ
untreated samples. (C) In vitro kinase assay as in A of the Flag Star–PAP complex puriﬁed from HEK-293 cells stably expressing Flag Star–PAP
after treatment with tBHQ (100mM for 4h) or the solvent control, DMSO with no exogenous substrate in presence of increasing amounts of PI4,5P2
(0, 25, 50 and 100mM). The
32P incorporated, total protein and the immunoblot for Star–PAP are indicated. (D) In vitro kinase assay as in C but
after the treatment with 100mM of CKI7 or 100mM IC261 prior to initiation of the kinase reaction. Control represents the untreated sample.
7964 Nucleic Acids Research, 2011,Vol.39, No. 18knockdown of CKIa with siRNA (Supplementary Figure
S3A for western) or pre-treatment with CKI inhibitors,
CKI7 and IC261, and the subsequent treatment with
tBHQ or DMSO (Supplementary Figure S3B). The
puriﬁed Star–PAP complex (Supplementary Figure S3B)
was then subjected to in vitro polyadenylation assays (24).
Star–PAP puriﬁed from the CKIa inhibitor treated cells
(CKI7 and IC261) diminished the Star–PAP
polyadenylation activity compared to the control cells
(Figure 3A and D). There was little polyadenylation
activity, which failed to be stimulated by tBHQ treatment
or the addition of PI4,5P2 (Figure 3D, lanes 1–8). The
addition of the CKI inhibitors (CKI7 and IC261) to
the polyadenylation reaction, however, did not affect the
Star–PAP polyadenylation activity (data not shown). The
loss of CKIa had a modest effect on the Star–PAP
polyadenylation activity and was less efﬁcient in the inhib-
ition of Star–PAP polyadenylation activity compared to
the CKI inhibitor treatments (Figure 3B and D) consistent
with the previous observation (26). The addition of
PI4,5P2 and/or tBHQ pre-treatment did show signiﬁcant
enhancement of the polyadenylation (Figure 3B).
Additionally, the Flag–Star–PAP complex puriﬁed from
cells transiently expressing a Star–PAP mutant with a
deletion within the proline rich region (residues 223–274)
(26), exhibited no polyadenylation activity (Figure 3C).
Taken together, these data suggest that phosphorylation
of Star–PAP by CKI modulates the Star–PAP
polyadenylation activity downstream of stimulation by
oxidant stress and phosphorylation primes Star–PAP, so
that it can be stimulated by PI4,5P2.
CKI activity is required for the efﬁcient 30-end processing
and expression of Star–PAP target mRNAs in vivo
We have shown that CKIa phosphorylates Star–PAP and
modulates Star–PAP’s polyadenylation activity. To
further examine the role of CKI activity in the expression
and 30-end processing of Star–PAP target messages, total
RNA was isolated from HEK-293 cells after transfection
with siRNA (control siRNA or siRNA speciﬁc for Star–
PAP or the associated kinase CKIa) (Figure 4D and E for
western) or treatment with the CKI inhibitor IC261 in the
Figure 2. Phosphorylation of Star–PAP is critical for its polyadenylation activity. (A) Immunoblot of Flag–Star–PAP puriﬁcation.
Sup=supernatant, F/T=Flow through, W=wash and E1-E3=elution fractions of Star–PAP the complex. (B) In vitro polyadenylation assay
of the Flag–Star–PAP complex puriﬁed from HEK-293 cells stably expressing Flag–Star–PAP after treatment with tBHQ (100mM for 4h) or the
solvent control, DMSO with or without the addition of PI4,5P2 and -phosphatase treatment of the protein. The cell puriﬁed Star–PAP was treated
with -phosphatase at RT for 30min and subjected to polyadenylation assay using (UAGGGA)5A15 oligo as described (24). The poly(A) tail and the
origin of the gel are indicated. (C) Quantiﬁcation of the poly(A) tail addition in B (upper panel) and western blot analysis of Star–PAP in each
reaction lane as of the PAP assay in B (lower panel). The intensity of radioactive
32P incorporation is expressed in arbitrary units.
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We then analyzed the total mRNA expression and the
measure of 30-end processed (polyadenylated, mature)
mRNA of Star–PAP direct target heme oxygenase-1
(HO-1) by RT–qPCR and 30-RACE assay, respectively.
As expected, RT–qPCR demonstrated an induction of
 15-fold of HO-1 expression after tBHQ treatment and
knockdown of endogenous Star–PAP or treatment with
CKI inhibitor IC261 ablated both basal and
stress-induced HO-1 mRNA levels (Figure 4A) (24,26).
Knockdown of CKIa did not inhibit tBHQ-induced
HO-1 message unlike the CKI inhibitor, IC261, which ef-
ﬁciently blocked the tBHQ-induced HO-1 expression
(Figure 4A) (26). The expression of the Star–PAP
non-target glutamate-cysteine ligase, catalytic subunit
(GCLC) was not affected by tBHQ treatment, CKIa
knockdown, or CKI inhibitor treatments (Figure 4B).
To further examine the role of CKI activity in the 30-end
processing of HO-1 pre-mRNA, the knockdown and in-
hibitor approach described above was employed, followed
by 30-RACE analysis from the total RNA to measure the
mature polyadenylated mRNA in the cell. Distinct RACE
products for HO-1 ( 700bp in length) were observed in
control cells with a large induction upon tBHQ stimula-
tion. HO-1 production was lost after the inhibition of
cellular CKI activity with IC261, demonstrating that
CKI activity is necessary for the processing of this Star–
PAP target mRNA (Figure 4C). Consistent with the ex-
pression proﬁle, CKIa knockdown was not effective in
blocking the 30-end processed (polyadenylated) mRNA
Figure 3. CKI-activity modulates Star–PAP polyadenylation activity. In vitro polyadenylation assays of cell-puriﬁed Flag–Star–PAP (A) after treat-
ment with tBHQ or DMSO in presence and absence of PI4,5P2 addition; (B) puriﬁed after knockdown of CKIa with siRNA followed by treatment
with tBHQ (100mM for 4h) or solvent control DMSO; (C) puriﬁed from HEK-293 cells transfected with a Star–PAP mutant construct that contains
a deletion of proline rich region; (D) puriﬁed after the treatment of the cells with CKIa inhibitors CKI7 and IC261. Control refers to the
polyadenylation assays carried out with untreated Star–PAP.
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glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was not affected by tBHQ treatment, CKIa knockdown,
or CKI inhibitor treatment (Figure 4C). These results
suggest that CKI activity is required for the expression
of Star–PAP target and that Star–PAP complex perhaps
contains other isoforms of CKI in addition to CKIa.
Star–PAP is an essential factor for the cleavage of its
target mRNA and Star–PAP recruits the cleavage factors
to the pre-mRNA (25). Therefore, we measured the HO-1
uncleaved mRNA levels to study the possible role of CKI
activity in the cleavage of Star–PAP target pre-mRNAs.
Consistent with the previous report (24), Star–PAP
knockdown resulted in  12-fold increase in the quantity
of uncleaved HO-1 mRNA relative to total HO-1 mRNA
(Figure 4F). Loss of CKIa or treatment with IC261 did
not exhibit any signiﬁcant change in the cleavage of HO-1
pre-mRNA (Figure 4F); suggesting that the regulation
Star–PAP target messages by CKI activity regulates
polyadenylation. Similarly, the association and assembly
of Star–PAP polyadenylaton complex did not appear to
be affected by CKI activity as demonstrated by western
analysis of key Star–PAP associated factors after the in-
hibition of CKI in the cell (Supplementary Figure S4A).
Another CKI isoform, CKIe associates with and
phosphorylates Star–PAP
CKIa knockdown only partially blocked the basal expres-
sion of HO-1 (26) and poorly blocked tBHQ stimulated
Star–PAP polyadenylation activity and the expression of
Star–PAP targets. Therefore it is possible that Star–PAP
complex associates with additional isoforms of CKI that
compensate for the loss of CKIa. To test this hypothesis,
Figure 4. CKI-activity is required for the expression and efﬁcient 30-end processing of Star–PAP target message. HEK-293 cells were transfected with
siRNA speciﬁc for endogenous Star–PAP or CKIa or treated with IC261 (100mM for 2.5h), then stimulated with the antioxidant tBHQ (100mM for
4h). Total RNA was extracted and analyzed by quantitative real-time RT–PCR for (A) HO-1 mRNA levels (B) and GCLC mRNA levels.
Normalized to GAPDH in each data set,±SEM, N 6. (C)3 0-RACE assay of HO-1 and GAPDH after HEK-293 cells were transfected with
siRNA speciﬁc for endogenous CKIa or inhibitors of CKI-activity and then stimulated with the antioxidant tBHQ (100mM for 4h). Data is
representative of N 3. (D and E) Western blot analysis of the siRNA knockdown of CKIa and Star–PAP. (F) Levels of uncleaved HO-1
pre-mRNA normalized to total mRNA from HEK 293 cells transfected with control, Star–PAP or CKIa speciﬁc siRNA, or after treatment with
CKI inhibitor IC261. Data is representative of N 3.
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Flag–Star–PAP complex and subjected it to kinase assay
with casein as a substrate. We observed that even after the
knock down of CKIa, signiﬁcant amount of kinase
activity was still associated with the Star–PAP complex
toward casein, which was equally-induced by tBHQ treat-
ment similar to the wild type cells (Figure 5A). This
suggests that Star–PAP complex contains additional
casein kinase(s) other than CKIa. Since, the kinase inhibi-
tors IC261 and CKI7 employed for our study also inhibits
CKIe and d (51) in addition to CKIa (26), we tested the
association of these isoforms in the Flag–puriﬁed Star–
PAP complex from the cell in the presence or absence of
tBHQ treatment. We observed the association of CKIe
but not d in the Star–PAP complex puriﬁed from cells
both with tBHQ treatment and without tBHQ treatment
(Figure 5B). Other casein kinases such as CKII did not
associate with the Star–PAP complex (Figure 5B). Control
protein, b-tubulin was also not detected in the Star–PAP
complex puriﬁed from the cell (Figure 5B), suggesting the
speciﬁcity of the proteins associated with the Star–PAP
complex.
We further investigated if CKIe phosphorylates Star–
PAP by an in vitro kinase assay. GST-tagged recombinant
full length CKIe was tested for its ability to phosphorylate
the heat inactivated Flag–tagged Star–PAP isolated from
the cell or His-tagged recombinant Star–PAP. We also
tested the activity of GST-CKIe with its generic kinase
substrate casein (Supplementary Figure S4B). We
observed the phosphorylation of both cell-puriﬁed
(Flag-tagged) (Figure 5D) and recombinant (His-tagged)
(Figure 5E) Star–PAP by CKIe. There was a dose
Figure 5. CKI isoform, CKIe associates with and phosphorylates Star–PAP. (A) In vitro kinase assay of the Flag–Star–PAP complex puriﬁed from
HEK-293 cells stably expressing Flag–Star–PAP after knockdown of CKIa with speciﬁc RNAi or control RNAi followed by treatment with tBHQ
(100mM for 4h) or DMSO using generic kinase substrate Casein. The
32P incorporated and the total protein (coomasie-stained) are indicated.
(B) Western analysis to detect the association of various CKI isoforms as indicated in the Flag-puriﬁed Star–PAP complex from the cell in presence
and absence of tBHQ treatment of the cell. Sup=Supernatant, F/T=Flow through, W=Wash, E=Elution fraction of the puriﬁcation.
(C) In vitro kinase assay of increasing amounts of CKIa with heat inactivated Flag puriﬁed Star–PAP as substrate. (D) In vitro kinase assay of
increasing amounts of CKIe with heat inactivated cell-puriﬁed Flag–Star–PAP as substrate. (E) In vitro kinase assay of increasing amounts of CKIe
with heat inactivated recombinant His-tagged Star–PAP as substrate. The
32P incorporated and the total protein (coomasie-stained) are indicated.
(F) In vitro kinase assay of CKIa and CKIe with Flag–Star–PAP full length (FL) and deleted for proline rich region (PRR) as substrate. The
32P
incorporated, the total protein (coomasie-stained) and the immunoblot are indicated.
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CKIe concentration for both the substrates (Figure 5D
and E). The control Flag-tagged CKIa also
phosphorylated the heat inactivated cell-puriﬁed Flag–
Star–PAP (Figure 5C) as previously described (26).
These results indicate that the associated CKIe can
directly phosphorylate Star–PAP.
Since CKIa phosphorylates Star–PAP in the proline
rich region, which splits the catalytic domain, we tested
if CKIe also shares the similar region of phosphorylation
on Star–PAP. Kinase assays were performed to test the
activity of GST-tagged CKIe toward Flag-puriﬁed Star–
PAP with deletion of the proline rich region, with CKIa as
control. As expected, both CKIa and CKIe exhibited
kinase activity toward full length (FL) Flag–Star–PAP
(Figure 5F). Remarkably, the GST–CKIe failed to phos-
phorylate the Star–PAP with deletion of proline rich
region (PRR) like CKIa, while there was intact
phosphorylation of full length Star–PAP (Figure 5F).
This suggests that both isoforms (a and e) share similar
region of phosphorylation on Star–PAP.
CKI isoforms a and e are required for the stressed
induced expression of Star–PAP target mRNA
Since CKIe phosphorylates Star–PAP and shares the
similar region of phosphorylation with CKIa,w e
investigated if CKIe has any role in the regulation of
Star–PAP target messages. RT–qPCR analysis was per-
formed with total RNAs isolated from cells after the
single knockdowns of CKIa and CKIe or together in the
presence or absence of tBHQ treatment (Figure 6D for
western). Consistent with above observations, there was
no loss of oxidative stress-induced expression after CKIa
knockdown (Figure 6A). Similarly, CKIe knockdown did
not signiﬁcantly impact tBHQ-induced expression of
Figure 6. CKI isoforms a and e are required for the stress-induced expression and efﬁcient 30-end processing of Star–PAP target message.
Quantitative real-time RT–PCR analysis for (A) HO-1 mRNA levels (B) and GCLC mRNA levels with the total RNAs from HEK-293 cells
transfected with siRNA speciﬁc for endogenous CKIa and CKIe separately or together followed by treatment with the antioxidant tBHQ
(100mM for 4h) or solvent DMSO. (C)3 0-RACE assay of HO-1 and GAPDH after HEK-293 cells were transfected with siRNA speciﬁc for
endogenous CKIa and CKIe separately or together then stimulated with the antioxidant tBHQ (100mM for 4h) or DMSO. Data is representative
of N 3. (D) Western blot analysis of the siRNA knockdown of CKIa and CKIe.( E) RIP analysis of HO-1 UTR by IP with antibodies speciﬁc to
RNA Pol II (RNAPII), Star–PAP, CKIa, and CKIe followed by reverse transcription-PCR with primers speciﬁc to HO-1 UTR region.
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both the isoforms (CKIa and CKIe) were knocked down
together, this blocked the expression of HO-1 (Figure 6A)
demonstrating that both kinases regulate expression of the
Star–PAP target HO-1, or that the two isoforms have re-
dundant function to regulate Star–PAP. The control
mRNA GCLC was not affected by either single or
double knockdowns of CKIa and CKIe (Figure 6B).
Similarly, by the 30-RACE assay which measures the
mature polyadenylated message from the cell, we
observed distinct signals from control resting cells,
stimulated by tBHQ treatment that were lost upon the
knockdown of Star–PAP (Figure 6C) as previously
described (25). Consistent with the total mRNA levels,
there was no signiﬁcant reduction in the RACE products
upon CKIa or CKIe knockdowns in presence of tBHQ
treatment compared to the control samples (Figure 6C).
Yet, when both isoforms (a and e) were knocked down,
there was complete loss of the RACE product
corroborating the above observation that CKIa and
CKIe are required for the expression of Star–PAP target
mRNA. The control non-target GAPDH was not affected
by either single or double knockdowns of CKIa and CKIe
(Figure 6C).
Star–PAP is a PAP that binds to pre-mRNA along with
other cleavage factors, assembling a distinct processing
complex on the 30-end of its target RNAs (25). In
addition, CKIa associates with HO-1 pre-mRNA (26)
perhaps by virtue of its interaction with Star–PAP 30-end
processing complex. Therefore, we investigated if CKIe
exhibits association with HO-1 pre-mRNA by an RIP ex-
periment. The cells were cross-linked with formaldehyde
and IP’ed using the respective antibodies followed by de-
tection of the associated RNA by RT–PCR using primers
speciﬁc to HO-1 30-UTR. As expected, we saw the associ-
ation of Star–PAP and CKIa similar to the control RNA
Pol II (Figure 6E). Interestingly, we also observed the as-
sociation of CKIe with HO-1 30-UTR RNA (Figure 6E)
supporting the above observations that CKIe also acts as
a part of Star–PAP 30-end processing complex.
DISCUSSION
Star–PAP activity is regulated by its phosphorylation
likely downstream of phosphoinositide and oxidative
stress signals. CKI protein kinase activity regulates Star–
PAP. A PI4,5P2 sensitive isoform, CKIa was
demonstrated to associate with and phosphorylate Star–
PAP within its catalytic region (26). Here, we show that
CKI activity mediated the phosphorylation of Star–PAP
that was stimulated by oxidative stress and this phosphor-
ylation was critical for both Star–PAP’s polyadenylation
activity and priming required for PI4,5P2 stimulation of
polymerase activity. Moreover, Star–PAP associated with
an additional CKI isoform, CKIe that compensated for
the loss of CKIa. CKIe, like CKIa, also phosphorylated
Star–PAP in the proline rich region (PRR). This indicated
that CKI kinase activity is critical for Star–PAP activity
and that CKIe acts as a functionally redundant isoform of
CKI that can complement for the loss of CKIa in the cell
to regulate Star–PAP. A single isoform of CKI may
regulate Star–PAP phosphorylation and HO-1 expression.
CKIa may be the major CKI isoform that modulates
Star–PAP downstream of oxidative stress. CKIe could
act as a substitute kinase to regulate Star–PAP’s control
of HO-1 processing and could act more speciﬁcally in
other pathways that regulate Star–PAP. A model depict-
ing CKIa/CKIe-mediated regulation of Star–PAP and
target messages is shown in Figure 7.
Gonzales et al. (26) showed that the CKIa phosphoryl-
ation site within the PRR of Star–PAP interrupts the cata-
lytic domain and this implied that phosphorylation of
Star–PAP could affect its enzymatic activity. Here, we
show that in addition to CKIa, CKIe also phosphorylates
Star–PAP in a similar region in the catalytic domain. This
phosphorylation modulates Star–PAP polyadenylation
activity and the expression of the Star–PAP target
HO-1. Similar regulation of PAP activity by phosphoryl-
ation was also reported for canonical PAPa (59,60),
although the mechanism of regulation is different. These
differences can be attributed to the distinct kinases and
stimuli responsible for the phosphorylation of the two
polymerases (59). PAPa is phosphorylated at the
C-terminal end by ERK kinase, whereas Star–PAP is
phosphorylated within the catalytic region by both
CKIa and CKIe (24,59,60). Inhibition of PAPa phosphor-
ylation resulted in a loss of polyadenylation activity.
Star–PAP phosphorylation is required for both
polyadenylation activity and its stimulation by PI4,5P2.
Since Star–PAP activity is speciﬁcally regulated by
Figure 7. A model depicting CKIa e mediated regulation of Star–PAP activity to modulate the 30-end processing of Star–PAP target mRNA.
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that the PI4,5P2 binding site overlaps with the CKI
phosphorylation sites or be regulated indirectly (24).
These data indicate that phosphorylation modulates sub-
strate recognition, PI4,5P2 binding or both to regulate
Star–PAP activity. The proline rich region in the catalytic
domain where both CKIa and e phosphorylate Star–PAP
contains a cluster of about 15 Ser/Thr residues which are
putative sites for CKI phosphorylation. Therefore, it is
likely that there is a complex phosphorylation pattern
involving multiple sites that are common or overlapping
for both the CKI isoforms.
Both the phosphorylation of Star–PAP by CKI
isoforms and Star–PAP activity are regulated by oxidative
stress. Yet, the association of CKIa or CKIe with Star–
PAP did not increase upon stimulation with oxidative
stress, suggesting that enhanced CKI kinase activity was
responsible for the increase in Star–PAP activity. The
mechanism of oxidant-induced CKI-regulated Star–PAP
activity remains elusive. CKI isoforms act as a down-
stream target of oxidative stress signal; however, the
current literature indicates that members of the CKI
family are constitutively active kinases (49).
Alternatively, an oxidative stress signal may induce
yet-to-be-identiﬁed nuclear factors that cooperate with
CKIa or CKIe to induce the phosphorylation of Star–
PAP. One similar example is the phosphorylation of mam-
malian IFNARI by CKIa, which is greatly induced by ER
stress (61).
CKIa or e are regulated by hierarchical priming in that
they can require prior phosphorylation by other protein
kinases to generate their substrate site for phosphorylation
(27). The CKI isoforms also spatially integrate into
protein complexes and this modulates their activity
toward proteins in those complexes (27,28,49). Both of
these properties may inﬂuence CKI control of Star–PAP
function. There are additional protein kinases that associ-
ate with the Star–PAP complex that are stimulated by
oxidative stress and these may deﬁne the hierarchical
priming of CKI isoforms for Star–PAP phosphorylation
and activity. The kinase that phosphorylates MBP has not
yet been identiﬁed, but may be a protein kinase that
deﬁnes hierarchical priming of the associated CKI
protein kinases.
Star–PAP regulation is integrated into multiple signal-
ing pathways (62). Different Star–PAP target genes are
speciﬁcally modulated by distinct signaling pathways indi-
vidually or synergistically (62). In addition, Star–
PAP-dependent mRNAs are speciﬁc to a select set of
messages (24–26). However, it is still unclear how the
Star–PAP dependent 30-end processing complex identiﬁes
the target mRNAs (25,62). One possibility is the direct
interaction of Star–PAP with certain sequence elements
on its target mRNAs as evidenced by its footprint on
the target HO-1 mRNA (25). Phosphorylation of Star–
PAP at distinct sites by various protein kinases could
also determine the target gene speciﬁcity or the signaling
to regulate Star–PAP. Moreover, the Star–PAP 30-end
processing complex associates with PIPKIa (24) and
protein kinases including CKIa and CKIe. It has been
reported that PIPKIa or CKIa are required for the
expression of some but not all Star–PAP target mRNAs
(24,26). Therefore, such proteins could also be involved in
modulating Star–PAP target speciﬁcity in addition to
regulating its polyadenylation activity.
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